Syntara expands SNT-9465 skin scarring study
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The study will maintain a blinded design and has added The Skin Hospital in Sydney as an additional clinical site to support this expansion. Top-line results from the study are now anticipated in the first quarter of the following year. Syntara's CEO expressed satisfaction with participant engagement, emphasizing the importance of capturing comprehensive data through this expanded cohort.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Syntara
- Appendix 4E and Annual Report
- Encouraging SNT-4728 Phase 2 iRBD results
- Results of Share Purchase Plan
- Share Purchase Plan Offer Booklet
- $8m placement and share purchase plan
Later from Syntara
- Further significant results from SNT-4728 iRBD Phase 2 trial
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara